Patent ID: 8476238
Filing Date: 2013-07-02
Classification: A61K,A61P

Abstract:
1. A method for inhibiting EGF receptor activity in lung cancer cells comprising contacting an EGF receptor with a pharmaceutical composition wherein the pharmaceutical composition comprises GMI or a recombinant thereof and an anti-cancer agent, wherein the GMI and the anti-cancer agent are in a synergistic amount in inhibiting EGF receptor in lung cancer cells, and wherein GMI has the amino acid sequences of: (1)-Leu-Ala-Trp-Asn-Val-Lys-(LAWNVK; SEQ ID NO:1) and (2)-Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV; SEQ ID NO:2) or the amino acid sequence of MSDTALIFTLAWNVKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVVVSGKD LGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3), and wherein the anti-cancer agent is cisplatin.